Form SCHEDULE 13D/A ENvue Medical, Inc. Filed by: Glibert Christian Michael
Tweet
Share
E-mail|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
|
ENvue Medical, Inc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
(CUSIP Number) |
Christian Glibert 4001 GREEN HERON SPRING DR, Carpinteria, CA, 93013 7405077228 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/22/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Glibert Christian Michael | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock |
| (b) | Name of Issuer:
ENvue Medical, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
969 PRUITT AVE,, TYLER,
TEXAS
, 77569. |
| Item 2. | Identity and Background |
| (a) | This Amendment No. 2 is being filed by Christian Michael Glibert. The citizenship, principal occupation, and background of the Reporting Person have not changed since the filing of the initial Schedule 13D |
| Item 3. | Source and Amount of Funds or Other Consideration |
Item 3 is hereby amended and supplemented by adding the following:
Not applicable. The transactions reported herein involve the disposition (sale) of securities of the Issuer, and no funds were expended by the Reporting Person | |
| Item 4. | Purpose of Transaction |
Item 4 is hereby amended and supplemented by adding the following:
This Amendment No. 2 is being filed to report that the Reporting Person has fully liquidated his investment position in the Issuer. On June 22, 2026, the Reporting Person disposed of all remaining shares of Common Stock of the Issuer held by him. Except as a result of the transactions described in Item 5, the Reporting Person has no current plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | Item 5 is hereby amended and restated in its entirety as follows:
(a) As of June 22, 2026, the Reporting Person beneficially owns 0 shares of Common Stock of the Issuer, representing 0.0% of the outstanding shares.
|
| (b) | (b) The Reporting Person has sole voting power and sole dispositive power over 0 shares of Common Stock, and shared voting power and shared dispositive power over 0 shares of Common Stock. |
| (c) | (c) On June 22, 2026, the Reporting Person disposed of an aggregate of 210,000 shares of Common Stock in open market transactions at a weighted average price of $0.6880 per share. The shares were sold in multiple tranches at prices ranging from $0.6756 to $0.7220.
|
| (d) | (d) Not applicable. |
| (e) | (e) On June 22, 2026, the Reporting Person ceased to be the beneficial owner of more than 5.0% of the Common Stock of the Issuer. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Item 6 is hereby amended and supplemented by adding the following:
The information set forth in Item 4 and Item 5 of this Amendment No. 2 is incorporated herein by reference. There are no contract arrangements, understandings, or relationships between the Reporting Person and any other person with respect to the securities of the Issuer. | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million
- ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions
- ENvue Medical secures $50M equity facility for growth and acquisitions
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13DSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
